[{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"LY3499446","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ National Comprehensive Cancer Network","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ National Comprehensive Cancer Network"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Care Access Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Abemaciclib","moa":"CDK","graph1":"Oncology","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Care Access Research \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Care Access Research \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Agilent Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Agilent Technologies","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Agilent Technologies"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlunestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"University of Tennessee Health Science Center","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Enobosarm","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"University of Tennessee Health Science Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Tennessee Health Science Center \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University of Tennessee Health Science Center \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"BBI-355","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Effector Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"INX-315","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyclix Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"INX-315","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyclix Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Imlunestrant","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vepdegestrant","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sermonix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Exactis Innovation","sponsor":"Sermonix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Partnership","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exactis Innovation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exactis Innovation \/ Sermonix","highestDevelopmentStatusID":"8","companyTruncated":"Exactis Innovation \/ Sermonix"}]
Find Clinical Drug Pipeline Developments & Deals for N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine
Details :
INX-315 is a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio (abemaciclib) and fulvestrant for the treatment of HR+/HER2- Breast Cancer.
Details :
LY3484356 (imlunestrant) is a brain-penetrant, oral selective estrogen receptor degrader (SERD), which is being evaluated for the treatment of ER+, HER2- Advanced Breast Cancer.
Details :
ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Details :
The collaboration aims to evaluate INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio (abemaciclib) and fulvestrant in HR+/HER2- Breast Cancer.
Details :
HLX78 (lasofoxifene) receives approval to join the ongoing global registrational ELAINE-3 trial with responsibility in China for the treatment of ER+/HER2 ESR1-mutated Breast Neoplasms.
Details :
Verzenio (abemaciclib) is a small molecule CDK4/CD6 inhibitor which is under phase 3 clinical development in combination with anastrozole for the treatment of post-menopausal patients with HR+/HER2-, advanced or metastatic breast cancer.
Details :
eFT226 (zotatifin) is a potent and sequence-selective small molecule inhibitor of the RNA helicase eIF4A. It is being evaluated in combination with fulvestrant and abemaciclib for treatment of ER+/HER2- advanced metastatic breast cancer.
Details :
VERU-024 (enobosarm), a selective androgen receptor modulator, into a Phase 2b clinical trial in combination with semaglutide to evaluate the efficacy and the safety of enobosarm to further increase fat loss.
Details :
Under the collaboration, Eli Lilly will supply CDK4/6 inhibitor Verzenio (abemaciclib) for use in combination with BBI-355, an oral, selective small molecule inhibitor of CHK1, in a clinical trial for locally advanced or metastatic solid tumors with onco...
Details :
VERU-024 (enobosarm), a first-in-class, oral, non-steroidal, selective androgen receptor agonist, which is investigating for the treatment of metastatic setting of AR+ER+HER2- breast cancer.
Reset All
